Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.

Kohei Shitara,Kei Muro,Yasuhiro Shimada,Shuichi Hironaka,Naotoshi Sugimoto,Yoshito Komatsu,Tomohiro Nishina,Kensei Yamaguchi,Y. Segawa,Yasushi Omuro,Takao Tamura,Toshihiko Doi,Seigo Yukisawa,Hirofumi Yasui,Fumio Nagashima,Masahiro Gotoh,Taito Esaki,Michael Emig,Kumari Chandrawansa,Astra M. Liepa,H. Wilke,Yukako Ichimiya,Atsushi Ohtsu

Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.

2016

Background We evaluated the safety and efficacy of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients previously treated for advanced gastric or gastroesophageal junction adenocarcinoma in Japanese and Western subgroups from the RAINBOW trial.

Keywords:

Ramucirumab
Medicine
Randomized controlled trial
Gastroesophageal Junction Adenocarcinoma
Pathology
Placebo
Paclitaxel
Cancer
Oncology
Survival rate
Internal medicine
Adenocarcinoma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations